Business
Xencor’s IL2-Fc Cytokine, XmAb®564, is Well-tolerated and Selectively Expands Regulatory T Cells in Phase 1a Clinical Study
-- Durable, dose-dependent and selective expansion of CD25bright Tregs, reaching a 117-fold increase over baseline at the highest dose -- -- Single dose of
About this update from Xencor, Inc.
[{"type":"text","content":"\n-- Durable, dose-dependent and selective expansion of CD25bright Tregs, reaching a 117-fold increase over baseline at the highest dose --\n\n-- Single dose of XmAb564 well-tolerated with no reported serious adverse events --\n\n-- First patient dosed in Phase 1b, multiple-ascending dose study in patients with atopic dermatitis or psoriasis --\n\n-- Phase 1a results to be presented in a webcast today at 4:30 p.m. ET --\n\n MONROVIA, Calif.--(BUSINESS WIRE)--\nXencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced topline clinical data from its Phase 1a single-dose, healthy volunteer study of XmAb®564, in development for patients with autoimmune diseases. XmAb564 is a wholly owned, monovalent interleukin-2 Fc fusion protein (IL-2-Fc), engineered with dramatically lowered potency and heightened binding affinity for the IL-2 alpha receptor (CD25), resulting in selective activation of regulatory T cells (Tregs). Tregs combat autoimmunity by suppressing other immune cells from attacking normal tissue; however, in many autoimmune diseases, Tregs become dysregulated.\n\n“The goal of an IL-2 therapy for autoimmune disease is to provide sustained low-intensity activation of Tregs while avoiding the pro-inflammatory systemic activation of effector T cells,” said John Desjarlais, Ph.D., senior vice president and chief scientific officer at Xencor. “We engineered XmAb564 with heightened affinity for IL-2’s alpha receptor (CD25) over its beta receptor to selectively target Tregs and with 400- to 1000-fold reduced potency to improve the half-life of XmAb564 and reduce its toxicity compared to wildtype IL-2. Fusion to our modular XmAb heterodimeric Fc domain with Xtend™ technology provides a stable protein scaffold and further enhances half-life. XmAb564’s design gave dramatic Treg increases and unprecedented durability for a single dose, with high levels of Treg populations sustained for at least 3 weeks.”\n\n“We have rapidly advanced XmAb564 through a first-in-human study and have now dosed the first patient in a newly initiated Phase 1b, multiple-ascending dose study in patients with atopic dermatitis and psoriasis,” said Allen Yang, M.D., Ph.D., senior vice president and chief medical officer at Xencor. “XmAb...